

## PRESS RELEASE

### ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated Project from Cell Line Development to GMP Manufacturing

Berlin, Germany and Cambridge, MA, USA, August 17, 2022

ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of their lead antibody candidate.

ProBioGen's [CHO.RiGHT](#)<sup>®</sup> cell line development including their latest [DirectedLuck](#)<sup>®</sup> transposase and platform processes enable the development to provide a high-expressing stable cell line and a robust manufacturing process. Further, ProBioGen's proprietary cell culture medium makes manufacturing processes even more robust, with improved protein titers and cell growth behavior. The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.

"We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard to treat cancers. We are thrilled to support them with our expertise and technology to move this candidate towards the clinic", says Dr. Gabriele Schneider, Chief Business Offer.

#### About ProBioGen

[ProBioGen](#) is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.

Combining both state-of-the-art development services, based on ProBioGen's [CHO.RiGHT](#) expression and manufacturing platform, together with intelligent product-specific technology yield biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 25 years. At three locations in Berlin, more than 250 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

#### About NextPoint Therapeutics

Founded by MPM Capital, [NextPoint Therapeutics, Inc.](#) has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer.

NextPoint's world renowned scientific founders recently discovered a novel checkpoint axis that is independent of PD-1/L1 and is present at high levels in many hard to treat cancers. This revolutionary discovery represents a previously unknown gateway to modulating both the adaptive and innate immune systems to find and destroy cancer cells.

#### ProBioGen Contact:

Dr. Gabriele Schneider  
Chief Business Officer  
[cdmo@probiogen.de](mailto:cdmo@probiogen.de)

#### ProBioGen Press Contact:

Sarah Wandrey  
Corporate Communications  
[press@probiogen.de](mailto:press@probiogen.de)

#### NextPoint Contact:

Paul Conrad  
Chief Business Officer  
[info@nextpointtx.com](mailto:info@nextpointtx.com)